Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.88 - $154.90
Previous CloseN/A
Volume185.86K
Average Volume (3M)6.32M
Market Cap
$1.79B
Enterprise Value$12.00B
Total Cash (Recent Filing)$522.76M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)19.6
Beta0.88
Next Earnings
Jul 30, 2025EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.60
Shares Outstanding98,277,030
10 Day Avg. Volume7,126,809
30 Day Avg. Volume6,318,245
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)29.47
Price to Sales (P/S)0.00
P/FCF Ratio-31.86
Enterprise Value/Market Cap6.69
Enterprise Value/Revenue1.65
Enterprise Value/Gross Profit6.63
Enterprise Value/Ebitda24.88
Forecast
1Y Price Target
$42.71Price Target Upside134.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Sarepta Therapeutics News
Bulls Say, Bears Say
Bulls Say
Profitability ProspectsManagement believes that the company can be profitable based on the ambulatory opportunity alone.
Regulatory EngagementThe FDA has proactively asked about the use of sirolimus, suggesting that Elevidys may not be completely removed from the market.
Bears Say
Market PenetrationThe inability to drive market penetration in the non-ambulatory setting represents a massive blow to the ELEVIDYS franchise.
Regulatory RisksThe FDA is evaluating the need for further regulatory action on ELEVIDYS after reports of patient deaths due to acute liver failure.
Safety ConcernsThe risk-benefit profile of ELEVIDYS is deteriorating following reports of fatality related to the drug.
Ownership Overview
4.12% Insiders
28.14% Mutual Funds
31.99% Other Institutional Investors
15.07% Public Companies and Individual Investors
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $16.88 and its highest was $154.90 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $1.79B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Jul 30, 2025 which is in 25 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on May 06, 2025. The company reported -$4.6 earnings per share for the quarter, missing the consensus estimate of -$3.207 by -$1.393.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.68.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 98,277,030 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$4.6 in its last earnings report, missing expectations of -$3.207. Following the earnings report the stock price went down -21.455%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.71 (134.16% Upside)
$42.71 (134.16% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 785.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.20%
12-Months-Change
Fundamentals
Return on Equity
-23.61%
Trailing 12-Months
Asset Growth
7.47%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strong demand projections for the future. However, challenges such as the tragic patient safety incident, administrative delays, and site capacity imbalances have led to a downward revision of revenue guidance. Despite these challenges, the company remains optimistic about long-term demand and continues to work on addressing the issues.Read More>SRPT Stock 12 Month Forecast
Average Price Target
$42.71
▲(134.16%Upside)
Technical Analysis
Alkermes
―
Blueprint Medicines
―
Axsome Therapeutics
―
Revolution Medicines
―
Legend Biotech
―